Biliary Tract Cancer

The FDA granted accelerated approval to zanidatamab-hrii for treatment of adults with previously treated unresectable or metastatic HER2-positive biliary tract cancer.

CHICAGO — Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced HER2-amplified biliary tract cancer, according to results of the phase 2B HERIZON-BTC-01 study presented at ASCO Annual Meeting.

The FDA approved pembrolizumab in combination with gemcitabine and cisplatin chemotherapy for adults with locally advanced unresectable or metastatic biliary tract cancer.

One-fifth of patients who underwent gallbladder cancer surgery at top-performing centers experienced related complications within 90 days, according to results of a retrospective study published in Annals of Surgical Oncology.

CHICAGO — Zanidatamab induced durable responses among patients with previously treated HER2-amplified biliary tract cancer, according to study results presented at ASCO Annual Meeting.

In this video, Daneng Li, MD, a medical oncologist at City of Hope, discussed results from the phase 3 KEYNOTE-966 study, presented at American Association for Cancer Research Annual Meeting.

In this video, Ahmed Kaseb, MD, CMQ, discussed results from the phase 3 KEYNOTE-966 study, presented at American Association for Cancer Research Annual Meeting.

In this video, James Cleary, MD, PhD, a medical oncologist at Dana-Farber Cancer Institute, discussed new developing treatment options for biliary tract cancer presented at American Association for Cancer Research Annual Meeting.

The addition of pembrolizumab to gemcitabine and cisplatin conferred a statistically significant and clinically meaningful survival benefit for patients with advanced biliary tract cancer, according to results of the KEYNOTE-966 study.

Cecilia Monge, MD, MPH, FACP, from the NCI Center for Cancer Research at NIH, discussed her ASCO Gastrointestinal Cancers Symposium presentation on racial and ethnic disparities in liver and biliary tract cancer clinical trials.